Compound News and Research

RSS

Amira initiates AM152 Phase 1 clinical study for fibrotic diseases

Amira Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects.

29 Oct 2010

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

Pfizer Inc. announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New England Journal of Medicine.

28 Oct 2010

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

28 Oct 2010

CutisPharma receives U.S patent for suppository compounding

CutisPharma, Inc. today announced that it has received approval from the United States Patent and Trademark Office for its patent (US 7,815,929) regarding a method for the preparation, storage and dispensing of compounded suppositories.

28 Oct 2010

Widely used fragranced products give off toxic chemicals

The sweet smell of fresh laundry may contain a sour note. Widely used fragranced products - including those that claim to be "green" - give off many chemicals that are not listed on the label, including some that are classified as toxic.

27 Oct 2010

Blocking receptor contributing to memory deficits may prevent memory loss after anesthesia

Memory loss after anesthesia is a common adverse event upon awakening from surgery. Unfortunately the cause of such memory loss is unknown and there are no known treatments or prevention strategies. A study published in the November 2010 issue of Anesthesiology indicates that this memory loss could be prevented by blocking a receptor thought to contribute to memory deficits. Such a treatment may be able to solve the feeling of mental confusion that surgical patients so often feel shortly after coming out of anesthesia.

27 Oct 2010

Anti-enolase antibody may contribute to bile duct injury in biliary atresia: Research

Researchers at the University of Colorado School of Medicine and The Children's Hospital have taken a big step toward understanding what causes one of the most serious liver diseases in infants.

27 Oct 2010

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Biogen Idec Inc. a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its third quarter 2010 results.

26 Oct 2010

New findings could deliver low-cost method to extract anticancer compound

A popular cancer drug could be produced cheaply and sustainably using stem cells derived from trees, a study suggests. Researchers have isolated and grown stem cells from a yew tree whose bark is a natural source of the anticancer compound paclitaxel. The development could enable the compound to be produced on a commercial scale at low cost, with no harmful by-products.

26 Oct 2010

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

26 Oct 2010

Researchers create new high-content assay to increase human embryonic stem cell survival

A new technique for increasing the survival rates of human embryonic stem cells will revolutionize their use in drug discovery and therapy. Human embryonic stem cells often die during the process of isolation using enzymatic disaggregation or low-density plating, which limits their usefulness in drug discovery and basic research. Similarly, the low rate of attachment of implanted cells hinders cell therapy.

25 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

Cholera outbreak kills 138, more than 1,500 other cases reported, Haitian health ministry officials say

Haitian Health Ministry officials have informed the World Health Organization that 138 deaths are a part of a fast-moving cholera outbreak north of Port-au-Prince, a U.N. official said, CNN reports.

25 Oct 2010

UCLA researchers receive grant to develop medical products against radiation exposure

Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.

25 Oct 2010

Intestinal microbiota can increase broccoli’s cancer-preventive power: Research

A University of Illinois study has shown for the first time that sulforaphane, the powerful cancer-fighting agent in broccoli, can be released from its parent compound by bacteria in the lower gut and absorbed into the body.

22 Oct 2010

Scorpion’s toxins can reduce heart bypass failures: Research

A toxin found in the venom of the Central American bark scorpion (Centruroides margaritatus) could hold the key to reducing heart bypass failures, according to research from the University of Leeds.

22 Oct 2010

Injecting apoA-V protein may reduce high triglyceride levels: Research

Injecting a protein that helps break down triglycerides may someday help treat an inherited form of high triglycerides, according to a new study in Arteriosclerosis, Thrombosis, and Vascular Biology, an American Heart Association journal.

22 Oct 2010

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-organ HCMV disease caused by multi-resistant virus. Details will be presented at the 48th IDSA meeting on October 23, presentation number LB-38.

22 Oct 2010

Biogen, Genentech announce new structure of anti-CD20 collaboration

Biogen Idec and Genentech, Inc. a wholly owned member of the Roche Group today announced that they have agreed to amend their collaboration on antibodies targeting CD20.

22 Oct 2010

Plant-derived compound for treatment of nicotine addiction also effective against alcoholism

South Dakota State University researchers have demonstrated for the first time that a plant-derived compound used to treat nicotine addiction also has significant effects against alcohol addiction.

21 Oct 2010

Compound News and Research

Amira initiates AM152 Phase 1 clinical study for fibrotic diseases

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

CutisPharma receives U.S patent for suppository compounding

Widely used fragranced products give off toxic chemicals

Blocking receptor contributing to memory deficits may prevent memory loss after anesthesia

Anti-enolase antibody may contribute to bile duct injury in biliary atresia: Research

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

New findings could deliver low-cost method to extract anticancer compound

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Researchers create new high-content assay to increase human embryonic stem cell survival

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

Cholera outbreak kills 138, more than 1,500 other cases reported, Haitian health ministry officials say

UCLA researchers receive grant to develop medical products against radiation exposure

Intestinal microbiota can increase broccoli’s cancer-preventive power: Research

Scorpion’s toxins can reduce heart bypass failures: Research

Injecting apoA-V protein may reduce high triglyceride levels: Research

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

Biogen, Genentech announce new structure of anti-CD20 collaboration

Plant-derived compound for treatment of nicotine addiction also effective against alcoholism

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News